Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.33 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23999654 | 1.00 | KDR (0.39) | KDRERBB2ALDH1A1GAAMAPT | |
| SCHEMBL23999676 | 0.88 | KDR (0.42) | KDRGAKRIPK2 | |
| SCHEMBL30180259 | 0.88 | KDR (0.42) | KDRGAKRIPK2 | |
| SCHEMBL30180266 | 0.84 | KDR (0.39) | KDR | |
| SCHEMBL23999443 | 0.84 | KDR (0.39) | KDR | |
| SCHEMBL23999895 | 0.81 | KDR (0.41) | KDRRIPK2 | |
| SCHEMBL30180298 | 0.81 | KDR (0.39) | KDRGAKRIPK2 | |
| SCHEMBL23999444 | 0.81 | KDR (0.39) | KDRGAKRIPK2 | |
| SCHEMBL23999476 | 0.80 | KDR (0.39) | KDRGAKRIPK2 | |
| SCHEMBL30180227 | 0.80 | KDR (0.39) | KDRGAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002511-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2025-01-02 | — | — | US | disclosed |
| EP-4426279-A1 | AKT3 MODULATORS | Georgiamune Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2023081854-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-4146666-A1 | AKT3 MODULATORS | Georgiamune LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146667-A1 | AKT3 MODULATORS | Georgiamune LLC (US) | 2023-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDR 3433/4885ERBB2 556/4885ALDH1A1 4544/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDR 3271/4885ERBB2 455/4885ALDH1A1 4541/4885 |
| US-20250002511-A1 | AKT3 MODULATORS | AKT3, PIK3C2A, PIK3C2B | KDR 1529/4885ERBB2 599/4885ALDH1A1 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.